Buy 5-MeO-DALT Cas 928822-98-4

Buy 5-MeO-DALT Cas 928822-98-4

5-MeO-DALT, also known as N,N-diallyl-5-methoxytryptamine or as foxtrot, is a psychedelic drug of the tryptamine and 5-methoxytryptamine families.^[1][3] It is taken orally.^[1]

5-MeO-DALT was first synthesized and described by Alexander Shulgin, who disclosed the compound in 2004.^[1][4] It has been encountered as a novel designer and recreational drug.^[4][5][6]

According to Alexander Shulgin in a follow-up entry to his book TiHKAL (Tryptamines I Have Known and Loved), the dose of 5-MeO-DALT is 12 to 20 mg orally and its duration is 2 to 4 hours.^[1][7] A wider dose range of 12 to 25 mg has also been reported.^[8] It is said to onset and peak remarkably quickly via the oral route, with an onset of less than 15 minutes and a time to peak of 30 minutes.^[1] The effects of 5-MeO-DALT were reported by Shulgin to include positive emotional changes, lightheadedness, increased appreciation of music and sex, and closed-eye visuals.^[1] There was said to be a lack of open-eye visuals and it was said to be relatively light in psychedelic character.^[1]

There is little published literature on the toxicity of 5-MeO-DALT.^[9] Case reports of overdose have been published, with effects including loss of consciousness, visual hallucinations, acute delirium, and rhabdomyolysis, among others.^[9][10][11] A death related to behavioral intoxication has been reported.^[3]

5-MeO-DALT activities

Target	Affinity (Ki, nM)
5-HT1A	3.26–48 (Ki) 2.9–3.4 (EC50Tooltip half-maximal effective concentration) 99–102% (EmaxTooltip maximal efficacy)
5-HT1B	551–735
5-HT1D	53–107
5-HT1E	322–500
5-HT1F	ND
5-HT2A	48–218 (Ki) 8.4–139.4 (EC50) 91–114% (Emax)
5-HT2B	45–59 (Ki) 18–33 (EC50) 86–90% (Emax)
5-HT2C	456–1,083 (Ki) 75–299a (EC50) 88–99%a (Emax)
5-HT3	>10,000
5-HT4	ND
5-HT5A	3,312
5-HT6	87–153
5-HT7	87–90
α1A–α1D	>10,000
α2A	215–228
α2B	726–956
α2C	1,467–641
β1–β3	>10,000
D1–D2	>10,000
D3	699
D4–D5	>10,000
H1	505–1,373
H2	4,250–>10,000
H3	2,820 (human) 1,712 (guinea pig)
H4	>10,000
M1–M5	>10,000
nAChTooltip Nicotinic acetylcholine receptor	>10,000
I1	ND
σ1	333 (human) 301–398 (rodent)
σ2	340 (human) 253 (rat)
TAAR1Tooltip Trace amine-associated receptor 1	ND
MORTooltip μ-Opioid receptor, DORTooltip δ-Opioid receptor	>10,000
KORTooltip κ-Opioid receptor	899–1,132
SERTTooltip Serotonin transporter	499–1,408 (Ki) >100,000 (IC50Tooltip half-maximal inhibitory concentration) (rat) 930–22,313 (IC50) (human) >100,000 (EC50) (rat)
NETTooltip Norepinephrine transporter	>10,000 (Ki) >100,000 (IC50) (rat) >100,000 (EC50) (rat)
DATTooltip Dopamine transporter	3,378 (Ki) >100,000 (IC50) (rat) >100,000 (EC50) (rat)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Footnotes: a = Stimulation of IP1Tooltip inositol phosphate formation. Refs: [12][13][14][15][16][17][18][19][20][21]

The interactions of 5-MeO-DALT with various targets have been reported.^{[14][15][16][20][18]} It binds to a variety of serotonin receptors, as well as a number of other targets.^{[14][15][16][20][22]} The drug is a potent full agonist of the serotonin 5-HT_1A and 5-HT_2A receptors.^{[16][17][19][18]} It is also an agonist of the serotonin 5-HT_2B and 5-HT_2C receptors.^[17]

Uniquely the substance displayed weak agonist-like activity at the μ-opioid (MOR) and δ-opioid receptors (DOR) along with more significant activity at the κ-opioid receptor (KOR) (∼76% of salvinorin A at 1 μM concentration) with G protein bias over β-arrestin activation.^[21]

Similarly to other psychedelics, 5-MeO-DALT produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.^[8][16][15] The drug fully substitutes for the serotonergic psychedelic DOM in rodent drug discrimination tests.^[23] Conversely, 5-MeO-DALT does not substitute for the entactogen MDMA in such tests.^[23] 5-MeO-DALT produces dose-dependent hyperlocomotion in rodents, followed by hypolocomotion at the highest assessed dose.^[23][16] This is in contrast to many other psychedelic tryptamines, which tend to produce only hypolocomotion.^[23] 5-MeO-DMT and 5-MeO-AMT are locomotor depressants, whereas 5-MeO-DET and 5-MeO-MiPT are mixed locomotor stimulants/depressants similarly to 5-MeO-DALT.^[23] It also produces hypothermia.^[16]

The head-twitch response induced by 5-MeO-DALT in rodents was found to be positively related to its serotonin 5-HT_2A receptor affinity and negatively related to its serotonin 5-HT_1A receptor affinity.^[15] In relation to this, multiple targets appear to contribute to the effects of 5-MeO-DALT.^[15][5]

The metabolism and cytochrome P450 inhibition of 5-MeO-DALT has been described in scientific literature.^{[9][24][25][26]}

The full name of the chemical is N–allyl–N-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1- amine. It is related to the compounds 5-MeO-DPT, DALT, 4-HO-DALT, and 4-AcO-DALT.

The chemical synthesis of 5-MeO-DALT has been described.^[1]

In April 2020, Chadeayne et al. solved the crystal structure of the freebase form of 5-MeO-DALT.^[27]

Analogues of 5-MeO-DALT include diallyltryptamine (DALT), 4-HO-DALT (daltocin), 4-AcO-DALT (dalcetin), NB-5-MeO-DALT, 5-MeO-DMT, 5-MeO-DET, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-MALT, 5-MeO-MiPT, and 5-MeO-iPALT (ASR-3001), among others.

The first material regarding the synthesis and effects of 5-MeO-DALT was sent from Alexander Shulgin to a research associate named Murple in May 2004, after which it was circulated online. In June 2004 5-MeO-DALT became available from internet research chemical vendors after being synthesized by commercial laboratories in China. In August 2004 the synthesis and effects of 5-MeO-DALT were published by Erowid.^[4] Shulgin has stated that 5-MeO-DALT had not previously existed in the scientific literature.^[1] 5-MeO-DALT was not included in the original published version of TiHKAL, but an entry for the compound was subsequently written and released in 2004.^[4] The drug was encountered as a novel designer drug by at least 2006.^[3][4][5][6]

5-MeO-DALT is not a controlled substance in Canada as of 2025.^[28]

As of October 2015 5-MeO-DALT is a controlled substance in China.^[29]

5-MeO-DALT became a controlled substance in Japan from April 2007, by amendment to the Pharmaceutical Affairs Law.^[30]

5-MeO-DALT is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.^[31]

Sveriges riksdag added 5-MeO-DALT to schedule I (“substances, plant materials and fungi which normally do not have medical use”) as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin.^[32]

5-MeO-DALT became a Class A drug in the UK on January 7, 2015 after an update to the tryptamine blanket ban.

5-MeO-DALT is not scheduled at the federal level in the United States,^[33] but it is likely that it could be considered an analog of 5-Meo-DiPT, which is a controlled substance in USA, or an analog of another tryptamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.

5-MeO-DALT is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.^[34]

5-MeO-DALT is a Schedule I controlled substance in the state of Louisiana making it illegal to buy, sell, or possess in Louisiana.^[35]

Anecdotal reports^[36] and a small-scale trial^[37] indicate the potential of 5-MeO-DALT for the treatment of cluster headache, one of the most excruciating conditions known to medicine.^[38] These observations are consistent with evidence of efficacy of other chemically-related indoleamines in the treatment of cluster headache.^[39]